Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2019

View Archived Issues

Cantargia announces start of CAN-10 development project for systemic sclerosis and myocarditis

Once-a-month oral contraceptive

Phase II data presented for KVD-001 in patients with diabetic macular edema

InMed receives CTA approval for phase I study of INM-755

First patient dosed in phase I study of BJ-001 in advanced or metastatic solid tumors

Discovery of novel inhaled JAK inhibitor for the treatment of respiratory diseases

DR-10601 shows promise for the treatment of type 2 diabetes and obesity in preclinical models

First preclinical data in DLBCL for BCMA-targeting 2 + 1 T-cell engager CC-93269

Innovent begins phase I study in China with anti-LAG-3 antibody IBI-110

CD3/CD7-IT causes clinical remission and rapid immune reconstitution in SR-aGvHD: phase I/II results

Quantitative and inducible modulation of the circadian clock with light using photocaged longdayisin

First-in-human data for novel oral multikinase inhibitor SKLB-1028 in R/R AML

With reduced toxicity, can HSCT make it to Hall of Fame?

AMR Centre patents new antibacterials

Vedanta initiates first-in-patient study of VE-800 with Opdivo in advanced or metastatic cancer

Guangzhou Henovcom Bioscience discloses ENPP2 inhibitors

Indivior selects CRO to conduct phase I study of INDV-2000

Nerviano Medical Sciences presents new IDH1 and/or IDH2 mutant inhibitors

Gilead Sciences identifies new benzamides for liver diseases

LAIMU synthesizes new compounds for allergy

FDA removes clinical hold on Abeona's phase III VIITAL study of EB-101

Sinovent studies small-molecule human URAT1 inhibitor XNW-3009 in phase I

Orca opens phase Ib study of TregGraft in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...